

# MINUTES

Utah Department of Health  
Drug Utilization Review Board

Thursday, February 12, 2015  
7:00 a.m. to 8:30 a.m.  
Cannon Health Building  
Room 125

**Board Members Present:**

Tony Dalpiaz, PharmD.  
Michael Symond, M.D.  
Keith Tolman, M.D.  
Jay Aldus, DDS  
Kyle Jones, M.D.

Mr. Kumar Shah  
George Hamblin, PharmD  
Susan Siegfried, M.D  
Mark Balk, PharmD.

**Board Members Excused:**

Jennifer Brinton, MD

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, Pharm.D  
Trevor Smith C.Ph.T.  
Heather Santacruz, R.N .

Lisa Hunt, RPh  
Merelynn Berrett, R.N.

**Other Individuals Present:**

Gary Oderda, UofU  
Mark Germann, Novartis  
Chris Draheim, Teva  
Pat Moty, Superius  
Clayne Garrett, Biogen Idec  
Charissa Anne, J&J  
Cody Ball, Select Health

Matt Sebt, Biogen Idec  
Cackie Hoffman, Novartis  
Lynda Oderda, UofU  
Scott Larson, BMS  
Joanita Lake, UofU  
Robert Nohavec, UofU Healthcare

---

**Meeting conducted by: Tony Dalpiaz, Pharm.D.**

---

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She said that there are no petitions for the board today.
3. **P&T Committee report** – Lisa Hunt said that the next P&T committee meeting will discuss diuretic agents. She passed out the tentative schedule for the rest of the year.
4. **Approval of prior meeting minutes** – Mike Symond made a motion to approve the January meeting minutes. Kumar Shah seconded the motion. All in favor.

5. **Nine month review** – Robyn Seely said that nine months ago, the DUR board made a motion to have a mutual exclusivity edit on Spiriva and Daliresp. She said that there have been no problems with this and the board motion will continue.
6. **Multiple Sclerosis Oral Agents (*teriflunomide (Aubagio)*, *fingolimod (Gilenya)* and *diethyl fumarate (Tecfidera)*** – Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about MS drugs in this class. Data was also presented about the utilization of the drugs in the Utah Medicaid population in previous years.

## 7. Public Comment

- a. Sharon Cahoon-Metzgen, Ph.D. (Tecfidera, Biogen ). She presented information about Tecfidera and offered to answer questions from the board. She requested that the board allow access to oral agents for patient who are non-compliant or adherent on injectable products.

## 8. Board Discussion on MS oral agents

- a. Robyn Seely presented the current PA criteria sheet for the agents. She said that a mutual exclusivity edit in the system to not allow more than one agent to be used at once.
- b. Mark Balk said that he agrees with what Robyn said about removing the PA requirements because of low usage in the class. He also said that it may be wise to have a quantity limits on the drugs to ensure proper dosing is made.
- c. Mark Balk made a motion to have no PA on the drugs, make a mutual exclusivity edit and to enact quantity limits on the MS oral drugs.
- d. Keith Tolman and Kumar Shah said that quantity limits should not be needed with these types of drugs. They went on to say that the limits can be cumbersome, especially when seeking a ninety day supply.
- e. Lisa Hunt said that quantity limits are for a maximum amount per month, not a lifetime maximum or 3 month supply. She said that Utah Medicaid clients are enrolled in the plan on a monthly basis, so only 30 day supplies of medications are permitted to be filled at a time.
- f. Mark Balk amended his motion to remove the PA criteria on the agents, and enable an automatic edit for mutual exclusivity, so the agents can't be filled together. Kyle Jones seconded the motion. All in favor.

## 9. Meeting Adjourned

The next DUR Board meeting is scheduled for Thursday, March 12<sup>th</sup>. The annual training meeting, and buprenorphine single agent product will be discussed.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)